GlaxoSmithKline plc (LON:GSK) insider Emma Walmsley bought 8 shares of GlaxoSmithKline stock in a transaction dated Thursday, January 10th. The stock was purchased at an average price of GBX 1,524 ($19.91) per share, for a total transaction of £121.92 ($159.31).
Emma Walmsley also recently made the following trade(s):
- On Tuesday, December 11th, Emma Walmsley bought 8 shares of GlaxoSmithKline stock. The stock was purchased at an average price of GBX 1,494 ($19.52) per share, for a total transaction of £119.52 ($156.17).
Shares of LON GSK opened at GBX 1,507.80 ($19.70) on Monday. GlaxoSmithKline plc has a 12-month low of GBX 1,235.20 ($16.14) and a 12-month high of GBX 1,724.50 ($22.53).
The business also recently declared a dividend, which was paid on Thursday, January 10th. Investors of record on Thursday, November 15th were given a dividend of GBX 19 ($0.25) per share. The ex-dividend date was Thursday, November 15th. This represents a yield of 1.26%.
GSK has been the topic of several recent analyst reports. Barclays restated an “overweight” rating on shares of GlaxoSmithKline in a research note on Monday, September 24th. Jefferies Financial Group restated a “buy” rating and issued a GBX 1,580 ($20.65) target price on shares of GlaxoSmithKline in a research note on Friday, October 12th. UBS Group restated a “buy” rating and issued a GBX 1,700 ($22.21) target price on shares of GlaxoSmithKline in a research note on Thursday, September 27th. Deutsche Bank set a GBX 1,520 ($19.86) target price on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Thursday, December 20th. Finally, Goldman Sachs Group set a GBX 1,900 ($24.83) target price on shares of GlaxoSmithKline and gave the company a “buy” rating in a research note on Tuesday, December 25th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company’s stock. GlaxoSmithKline has a consensus rating of “Hold” and a consensus target price of GBX 1,530.34 ($20.00).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: What is a blue-chip stock?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.